Table 1
PatientAge (years)Primary diseaseClinical manifestations of MASTreatment
Dg.DurationTreatment prior to MAS
L.H., female23JIA11 yearsMTXhepatosplenomegaly, increase of ALT, AST, pancytopenia, serositisGC high doses (i.v. pulses), cyclosporine
P.V., male20RA2 yearsMTX, SASfever, pancytopenia, hepatosplenomegaly, increase of ALT, AST, pericarditisGC high doses (oral), cyclosporine
P.D., male32AODS3 yearsMTXfever, hepatosplenomegaly, increase of ALT, AST, pancytopenia,GC high doses (oral)
V.N., female33AODS9 monthsMP, AZAfever, pancytopenia, hepatosplenomegaly, increase of ALT, AST, alveolar hemorrhageGC high doses (i.v. pulses), cyclosporine, tocilizumab